非高密度脂蛋白胆固醇与早发心血管疾病研究

杨 爽1, 刘晓 堃2
1.华北理工大学 2.唐山工人医院

摘要

目的：动脉粥样硬化性心血管疾病(Atherosclerotic cardiovascular disease ,ASCVD）仍是全球范围内致死率和致残率的主要原因，近年来，ASCVD 发病趋于年轻化，早发 ASCVD 占整个 ASCVD 人群中占比估计为 20%，带来了严重的医疗资源及社会经济的负担。非高密度脂蛋白胆固醇（Non–High-Density Lipoprotein Cholesterol，non-HDL-C）包括了较多的致动脉粥样硬化脂蛋白胆固醇，目前国内外研究发现 non-HDL-C 对早发 ASCVD 的发病预测价值较高，部分研究表明 non-HDL-C 预测价值甚至超过传统血脂指标，现就其研究进展做一综述。

关键词

非高密度脂蛋白胆固醇；早发心血管疾病；危险因素

参考

[1]中国心血管健康与疾病报告编写组.中国心血管健康与疾病报 告 2021 概 要 [J]. 中 国 循 环 杂 志 ,2022,37(6):553-578. DOI:10.3969/j.issn.1000-3614.2022.06.001. [2] Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298(7):776-785. doi:10.1001/jama.298.7.776 [3] Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112(22):3375-3383. doi:10.1161/CIRCULATIONAHA.104.532499 [4] Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. J Clin Lipidol. 2015;9(2):129-169. doi:10.1016/j.jacl.2015.02.003 [5] Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):3024-3025] [published correction appears in J Am Coll Cardiol. 2015 Dec 22;66(24):2812]. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934. doi:10.1016/j.jacc.2013.11.002 [6] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J. 2020 Nov 21;41(44):4255]. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455 [7] Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14(1):1-10. doi:10.1007/s11883-011-0219-7 [8] Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):121-37. doi: 10.1097/HJR.0b013e3283294b1d. PMID: 19287307. [9] Harari G, Green MS, Magid A, Zelber-Sagi S. Usefulness of Non-High-Density Lipoprotein Cholesterol as a Predictor of Cardiovascular Disease Mortality in Men in 22-Year Follow-Up. Am JCardiol. 2017;119(8):1193-1198. doi:10.1016/j.amjcard.2017.01.008 [10] Rallidis LS, Pitsavos C, Panagiotakos DB, Sinos L, Stefanadis C, Kremastinos DT. Non-high density lipoprotein cholesterol is the best discriminator of myocardial infarction in young individuals. Atherosclerosis. 2005;179(2):305-309. doi:10.1016/j.atherosclerosis.2004.09.022 [11] Dugani SB, Moorthy MV, Li C, et al. Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. JAMA Cardiol. 2021;6(4):437-447. doi:10.1001/jamacardio.2020.7073 [12] Brunner FJ, Waldeyer C, Ojeda F, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium [published correction appears in Lancet. 2019 Dec 6;:] [published correction appears in Lancet. 2020 Jan 4;395(10217):32]. Lancet. 2019;394(10215):2173-2183. doi:10.1016/S0140-6736(19)32519-X [13] Pencina KM, Thanassoulis G, Wilkins JT, et al. Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention. J Am Coll Cardiol. 2019;74(1):70-79. doi:10.10 16/j.jacc.2019.04.047 [14] US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement [published correction appears in JAMA. 2020 Feb 18;323(7):669] [published correction appears in JAMA. 2020 Feb 18;323(7):669-670]. JAMA. 2016;316(19):1997-2007. doi:10.1001/jama.2016.15450 [15] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in J Am Coll Cardiol. 2019 Jun 25;73(24):3237-3241]. J Am Coll Cardiol. 2019;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003 [16] Kohli-Lynch CN, Bellows BK, Thanassoulis G, et al. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. JAMA Cardiol. 2019;4(10):969-977. doi:10.1001/jamacardio.2019.2851 [17] Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol. 2018;15(4):230-240. doi:10.1038/nrcardio.2017.154 [18] AroraS, Stouffer GA, Kucharska-Newton AM,etal. Twenty year trends and sex differences in young adults hospitalized with acute myocardial infarction. Circulation 2019; 139:1047–56. [19] Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013 [published correction appears in Lancet. 2014 Aug 30;384(9945):746]. Lancet. 2014;384(9945):766-781. doi:10.1016/S0140-6736(14)60460-8 作者简介 杨爽，女，汉族，1996 年 1 月，河北唐山，研究生学历，华北理工大学硕士在读，心血管内科专业，主要从事于血脂与心血管疾病的相关研究，住院医师 通讯作者 刘晓堃 男 汉族 1970 年 6 月 河北唐山 博士研究生 心血管系统疾病